Age related macular degeneration (AMD) Clinical Trials

13 recruitingLast updated: June 18, 2026

There are 13 actively recruiting age related macular degeneration (amd) clinical trials across 14 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1. Top locations include Erie, Pennsylvania, United States, Katy, Texas, United States, Bellaire, Texas, United States. Updated daily from ClinicalTrials.gov.


Age related macular degeneration (AMD) Trials at a Glance

13 actively recruiting trials for age related macular degeneration (amd) are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Not Applicable with 5 trials, with the heaviest enrollment activity in Erie, Katy, and Bellaire. Lead sponsors running age related macular degeneration (amd) studies include National Taiwan University Hospital, Fondazione G.B. Bietti, IRCCS, and Australian National University (ANU).

Browse age related macular degeneration (amd) trials by phase

Treatments under study

About Age related macular degeneration (AMD) Clinical Trials

Looking for clinical trials for Age related macular degeneration (AMD)? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Age related macular degeneration (AMD) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Age related macular degeneration (AMD) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Not Applicable

Proteomic Biomarker Identification in Age-Related Macular Degeneration, Diabetic Retinopathy and Retinal Detachment

Age related macular degeneration (AMD)Diabetic Retinopathy (DR)Retinal Detachment
Fondazione G.B. Bietti, IRCCS260 enrolled1 locationNCT07500324
Recruiting
Phase 3

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled216 locationsNCT06541704
Recruiting

Enhanced Vision and Imaging Tests for Enabling Treatment Trials in Early and Intermediate AMD

Age related macular degeneration (AMD)
Maximilian Pfau150 enrolled1 locationNCT07515521
Recruiting
Not Applicable

International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study

Age related macular degeneration (AMD)
VisionCare, Inc.44 enrolled12 locationsNCT07164378
Recruiting
Not Applicable

Active AMD Study to Improve Function in Veterans

Age related macular degeneration (AMD)
VA Office of Research and Development70 enrolled1 locationNCT05932069
Recruiting

EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).

Age related macular degeneration (AMD)
Insel Gruppe AG, University Hospital Bern50 enrolled1 locationNCT07434713
Recruiting
Phase 2

Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy

Age related macular degeneration (AMD)
Assistance Publique - Hôpitaux de Paris90 enrolled1 locationNCT04292080
Recruiting
Phase 2

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Age related macular degeneration (AMD)Geographic Atrophy (GA)
ONL Therapeutics324 enrolled28 locationsNCT06659445
Recruiting
Not Applicable

Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics

Age related macular degeneration (AMD)Diabetic Retinopathy (DR)
National Taiwan University Hospital4,300 enrolled1 locationNCT07069647
Recruiting
Phase 1Phase 2

Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

wet age related macular degeneration (AMD)
Fujian Haixi Pharmaceuticals Co., Ltd.198 enrolled1 locationNCT07185841
Recruiting

Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration

Age related macular degeneration (AMD)
iHealthScreen Inc1,076 enrolled1 locationNCT07084883
Recruiting
Not Applicable

Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening

Age related macular degeneration (AMD)Diabetic Retinopathy (DR)
National Taiwan University Hospital1,000 enrolled1 locationNCT06843499
Recruiting
Phase 3

The RAAMP study. Ranibizumab versus aflibercept for age-related macular degeneration, using multifocal objective pupil perimetry.

wet age related macular degeneration (AMD)
Australian National University (ANU)60 enrolled2 locationsACTRN12614000497606